Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FID-007 in Combination With Cetuximab in Advanced HNSCC
NCT06332092Phase 2Active, not recruiting
- Sponsor
- Fulgent Pharma
- Start
- Apr 2024
- Primary completion
- Dec 2025
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fid-007 in head and neck squamous cell carcinoma (HNSCC), sponsored by Fulgent Pharma. Started Apr 2024; status: active, not recruiting.
02
Drugs
fid-007
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06332092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332092.